Last reviewed · How we verify
Changchun Keygen Biological Products Co., Ltd. — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| varicella-1 | varicella-1 | marketed | ||||
| live attenuated JE vaccine | live attenuated JE vaccine | marketed | ||||
| varicella-5 | varicella-5 | marketed | Live attenuated vaccine | Varicella-zoster virus | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bandim Health Project · 1 shared drug class
- Beijing Center for Disease Control and Prevention · 1 shared drug class
- Bharat Biotech International Limited · 1 shared drug class
- Canadian Immunization Research Network · 1 shared drug class
- Center for Research and Production of Vaccines and Biologicals, Vietnam · 1 shared drug class
- Centers for Disease Control and Prevention · 1 shared drug class
- Changchun BCHT Biotechnology Co. · 1 shared drug class
- Aga Khan University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Changchun Keygen Biological Products Co., Ltd.:
- Changchun Keygen Biological Products Co., Ltd. pipeline updates — RSS
- Changchun Keygen Biological Products Co., Ltd. pipeline updates — Atom
- Changchun Keygen Biological Products Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Changchun Keygen Biological Products Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/changchun-keygen-biological-products-co-ltd. Accessed 2026-05-17.